Transforming Women’s Health
and Fertility Care

WHAT WE DO

AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.

AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is done transvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF.

A TRANSFORMATIVE APPROACH TO PCOS INFERTILITY TREATMENT

1
Effective
Proven as effective as injections and IVF, with effects lasting for several years.
2
Less invasive
Simple, short, transvaginal procedure not requiring surgery or general anesthesia.
3
Less Risky
No increased risk of multiple pregnancies or ovarian hyperstimulation.
4
Less Medicalised
Not requiring intense monitoring and enabling natural pregnancy.

LATEST NEWS

Pre-clinical experiments have successfully evaluated the safety and usability profile of the AblaCare Procedure, Ovarian Rebalancing. AblaCare has also finalised the development of its device, and is currently preparing for clinical trials. The AblaCare device is for investigational use only and is not marketed in any geography to date.

Our Team

Anne Osdoit - CEO
Anne is a biomedical engineer and seasoned medtech entrepreneur, having already supervized the development, clinical validation and commercial launch of innovative medical devices.
Marion Gasperment - COO
Marion is an experienced program manager in medtech start-ups in the early phases of their clinical experience. She is leading the operational and clinical efforts for AblaCare.
Tim Lehinan - CTO
Tim is an experienced developer of new medical technologies, having worked in various engineering and regulatory positions in the medical device industry over the last 30 years both in the US and Europe.
Gérard Hascöet - Chairman
Gérard is a serial medtech entrepreneur. He founded successful companies such as Technomed International, IMMI and Sometec. Gérard is also co-founder and President of MD Start, and Venture Partner at Sofinnova.

Want to LEARN more?

Over 10% of women worldwide are affected by PolyCystic Ovary Syndrome, a leading cause of female infertility.

At AblaCare, we are developing an innovative treatment for PCOS infertility which would be less risky and less invasive than current options.

A SIMPLE, OFFICE BASED
ULTRASOUND-GUIDED PROCEDURE

The AblaCare procedure, Ovarian Rebalancing, improves upon the clinical success of a demonstrated surgical approach and transforms it into a simple, office-based treatment. The approach consists in correcting the hormonal imbalance of PCOS patients and restoring the normal function of the ovaries. This is done by reducing the ovarian tissue volume responsible for the hormonal imbalance preventing ovulation
EFFECTIVE
APPROACH

Same mechanism of action as "ovarian diathermy or drilling" :

- restoring ovulation by ablating ovarian tissue to achieve non-specific volume reduction

- with proven efficacy documented in large body of literature and guidelines

SAFE PROCEDURE & DEDICATED DEVICE

- Built-in safety features to ensure correct placement and energy delivery

- Limited thermal damage to ovary surface

- Bipolar energy, low power, reproducible ablation

BASED ON KNOWN
ACCESS

- Same as for ovocyte retrievals: can be performed in office setting

- Ultrasound visualisation for device placement

- Transvaginal, needle-based access

Contact Us